🧬Tidera Health
⚕️

Educational tool only. Does not confirm eligibility or provide medical advice. Always consult your physician before pursuing any trial.

OncologyICD-10: C25

Find Recruiting Clinical Trials for Pancreatic Cancer

Search PDAC, KRAS-targeted, immunotherapy, and early-detection pancreatic cancer trials — matched to your stage and molecular profile.

🔍 Search Pancreatic Cancer Trials →

About Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with a 5-year survival rate under 12%. Approximately 80% of patients present with locally advanced or metastatic disease at diagnosis, when curative surgery is no longer possible. Standard treatment includes gemcitabine + nab-paclitaxel or FOLFIRINOX for metastatic disease, but median overall survival remains approximately 8–12 months. The near-universal presence of KRAS mutations (95% of PDAC) has historically been undruggable, but novel KRAS G12D and pan-KRAS inhibitors represent a major breakthrough currently in clinical trials.

What Types of Pancreatic Cancer Clinical Trials Exist?

Pancreatic cancer trials are in a critical phase of development. KRAS-targeted therapies — particularly KRAS G12D inhibitors — are generating significant early results. Other active programs include PARP inhibitors for BRCA-mutant PDAC, mRNA vaccine approaches, CAR-T cell therapies, stroma-disrupting agents (to improve drug penetration), and immune checkpoint combinations. For resected/adjuvant disease: PARP inhibitors in BRCA-mutant PDAC (olaparib), chemotherapy intensification, and radioimmunotherapy combinations. KRAS mutation status (G12D, G12V, G12C specific), BRCA1/2 status, and disease stage are critical eligibility variables.

Find Recruiting Pancreatic Cancer Trials Near You

Enter your profile and we'll search ClinicalTrials.gov in real time — matching trials to your age, location, and treatment history. Free, no account required.

Search Pancreatic Cancer Trials →

Data from ClinicalTrials.gov · Updated in real time · Educational use only

Frequently Asked Questions

What clinical trials are available for pancreatic cancer?▾
Recruiting pancreatic cancer trials include KRAS G12D inhibitors (a major breakthrough currently in early trials), KRAS G12C inhibitors, PARP inhibitors for BRCA-mutant PDAC, CAR-T cell therapies, mRNA cancer vaccines, stroma-targeting agents, checkpoint inhibitor combinations, and surgical/radiotherapy optimization trials for borderline resectable disease.
How does KRAS mutation status affect pancreatic cancer trial eligibility?▾
KRAS mutation status is increasingly critical. Approximately 32% of PDAC has KRAS G12D mutations, 22% KRAS G12V, and 2% KRAS G12C (the first KRAS mutation to have approved targeted therapy). Novel KRAS inhibitors in clinical trials target specific mutation variants. Molecular profiling of tumor tissue (or liquid biopsy ctDNA) is required to determine KRAS variant status.
Are there pancreatic cancer trials for BRCA-mutated patients?▾
Yes. BRCA1/2 germline mutations occur in approximately 5–7% of PDAC patients and confer sensitivity to platinum-based chemotherapy and PARP inhibitors. Olaparib (PARP inhibitor) is FDA-approved for maintenance therapy in BRCA-mutant metastatic PDAC after platinum-based first-line treatment. Additional PARP inhibitor and DNA damage response trials specifically recruit BRCA-mutant or HRD-positive PDAC patients.

Related Conditions

Colorectal CancerOvarian CancerLung Cancer

Data source: All clinical trial information is sourced from ClinicalTrials.gov, the official U.S. registry maintained by the National Library of Medicine. Tidera Health is an independent educational platform and is not affiliated with ClinicalTrials.gov or the National Library of Medicine. Always verify trial details directly with the research coordinator or your physician.